RBP4: A Culprit for Insulin Resistance in End Stage Renal Disease That Can Be Cleared by Hemodiafiltration by Grosjean, F. et al.
Research Article
RBP4: A Culprit for Insulin Resistance in End Stage Renal
Disease That Can Be Cleared by Hemodiafiltration
Fabrizio Grosjean, Pasquale Esposito, Rosario Maccarrone, Carmelo Libetta,
Antonio Dal Canton, and Teresa Rampino
Nephrology, Dialysis, Transplant, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy
Correspondence should be addressed to Fabrizio Grosjean; fabrizio.grosjean@gmail.com
Received 29 June 2017; Revised 27 October 2017; Accepted 1 November 2017; Published 23 November 2017
Academic Editor: Fabrizio Montecucco
Copyright © 2017 Fabrizio Grosjean et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Introduction. Retinol Binding Protein 4 (RBP4) is mainly excreted by the kidney and plays a pivotal role in insulin resistance (IR).
In our study, we evaluated the association between RBP4 and IR in hemodialysis subjects (HD). We also assessed how circulating
RBP4 could be influenced by kidney transplant or different dialytic techniques. Methods. RBP4 serum levels were evaluated in
HD (𝑛 = 16) and matched healthy controls (C; 𝑛 = 16). RBP4 and glucose transporter type 4 (GLUT4) mRNA expressions were
also determined in adipose tissue. Circulating RBP4 was evaluated after kidney transplant (𝑛 = 7) and in hemodialysis patients
(𝑛 = 10) enrolled in a cross-over study treated with standard bicarbonate dialysis (BD) or hemodiafiltration (HDF).Results. HOMA
index (𝑃 < 0.05) and serum RBP4 (𝑃 < 0.005) were higher in HD compared to C. RBP4 levels positively correlated with fasting
serum glucose (𝑃 < 0.05). RBP4 mRNAwas lower in HD compared to C (𝑃 < 0.05) and positively correlated with kidney function
(𝑃 < 0.05) andGLUT4mRNA (𝑃 < 0.001). Transplant orHDF reduced circulating RBP4 (𝑃 < 0.01 and𝑃 < 0.05, resp.). Our results
demonstrate that IR is associated with high circulating RBP4 and that suppressed RBP4 adipose tissue expression is accompanied
by reduced GLUT4 expression in HD. Renal transplantation or HDF are effective in lowering serum RBP4 levels.
1. Introduction
Insulin resistance (IR) is common in patients with chronic
kidney disease (CKD) and it often occurs in early stages of the
renal impairment (glomerular filtration rate < 60mL/min)
[1]. IR is defined by normal fasting serum glucose associated
with high serum insulin levels, a state that results in type 2
diabetes when the increased insulin secretion is no longer
able to compensate for impaired peripheral insulin respon-
siveness [2]. IR has a particularly relevant clinical impact in
End Stage Renal Disease (ESRD) because it adds independent
cardiovascular risk in patients who are rated as having an
inherent increased cardiovascular (CV) risk and 10-time
higher mortality for CV events than the general population
[3–6]. As yet, the mechanisms underlying IR in CKD are
far from being fully understood. Possible culprits include
low tolerance to physical activity, sedentary life style, toxins
no longer cleared by the failing kidneys, and an endocrine
dysfunction of adipose tissue [7–12]. Retinol Binding Protein
4 (RBP4) is a 21 KDa protein produced by the adipocytes that
is secreted in the circulation where it binds transthyretin,
giving origin to 80KDa complex that carries vitamin A
(retinol) to the target tissues. After having released retinol,
this macromolecular complex splits up and RBP4 is freely
filtered by the glomeruli; then it is partially reabsorbed and
catabolized by the proximal tubules and it is excreted into the
urine [13, 14]. Free RBP4 participates in glucose metabolism
by inducing gluconeogenesis in liver cells and inhibiting
glucose uptake in muscle cells. These combined effects raise
plasma glucose and trigger insulin secretion, eventually
resulting in the scenario of IR. Studies in rodents have
shown that RBP4 production is inversely related to adipocyte
expression of glucose transporter type 4 (GLUT4), an insulin
dependent glucose transporter that induces glucose uptake
in fat and muscle, and that GLUT4 expression is reduced in
adipocytes but not in muscle cells in IR [8, 12, 15–17]. It has
also been shown that RBP4 can reduce GLUT4 expression in
adipocytes and that it can indirectly inhibit insulin signalling
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in adipocytes by inducing release of inflammatory cytokines
in macrophages [18, 19]. Furthermore, high RBP4 levels have
been observed in obese subjects, type 2 diabetic patients,
adolescents with cardiovascular risk factors, and nonobese
individuals low insulin sensitivity suggesting a pathogenic
link betweenRBP4 and IR in humans [20–23]. Based on these
findings we have investigated the association between RBP4
and IR in ESRD patients. Because RBP4 is mainly excreted
by the kidney and it has been described that molecules with
molecular weight similar to RBP4 are cleared efficiently by
hemodiafiltration (HDF) rather than by standard bicarbonate
dialysis (BD), we assessed how RBP4 levels are influenced
by kidney transplant or different extracorporeal dialysis
techniques.
2. Materials and Methods
2.1. Study Design. We enrolled patients undergoing standard
hemodialysis (HD) for at least 3 months in our Unit of
Nephrology, who were on kidney transplant waiting list.
Exclusion criteria were diabetes or glucose intolerance,
malignancies, acute and chronic active infections, malnutri-
tion, and failure of the vascular access. Matched healthy sub-
jects were enrolled as controls (C).Normal renal functionwas
defined as normal serum creatinine (lower than 1.2mg/dL)
and glomerular filtration rate (GFR) estimated with Cockroft
and Gault formula greater than 60mL/min with normal
urinalysis. Malnutrition, diabetes, and impaired glucose tol-
erance were defined according to established criteria [24–26].
To evaluate the effect of different dialysis technique on RBP4
circulating levels we included in the present study further
unselected ESRD patients enrolled in a previous cross-over
study (BD versus HDF, 3-month treatment, 𝑛 = 10). Age, sex,
24 h diuresis for hemodialysis (HD), history of hypertension,
cardiovascular events, smoking, alcohol abuse, physical activ-
ity and regular drug use, malignancies and active infections,
familiar history of diabetes, and cardiovascular events were
recorded at the enrolment. Alcohol abuse was defined as
consumption greater than 25 g per day, residual diuresis in
HD patients as a urine volume greater than 500mL per day,
and physical activity as aerobic exercises for at least 30min
three times a week. We measured blood pressure, heart rate,
body weight, and height and we derived the Body Mass
Index (BMI). The degree of insulin resistance/sensitivity was
derived with the “homeostatic model assessment (HOMA)
index”: fasting serum glucose [mMol/L] × fasting serum
insulin/22.5 [26]. The protocol was approved by the Ethi-
cal Board of our Institution (P-20080008696), and it was
funded by the Fondazione IRCCS Policlinico San Matteo
(08054303/10).
2.2. Serum RBP4 Levels Quantification. Blood samples were
obtained from all HD patients soon before the dialysis
session and at the end of the same session when needed
to evaluate dialysis RBP4 removal. Blood samples were
also obtained from HD patients receiving kidney graft 12
months after transplant. RBP4 was measured in serum
obtained from 3ml of blood and then stored at –80∘C within
30min of sampling. Serum RBP4 levels were quantified by
ELISA (Pantec, Marburg, Germany) following manufacturer
instructions.
2.3. Adipose RBP4 and GLUT4 Gene Expression. RBP4 and
GLUT4 mRNA expression was evaluated in adipose tissue
obtained from 13 subjects, 7 were on HD and 6 were healthy
controls (C). 4 HD subjects were matched with 4 controls
for age, sex, and BMI. Adipose tissue was collected from
HD patients during kidney transplant surgical procedure
soon before the graft, while control adipose tissue was
obtained from healthy subject during cold hernia surgical
correction. Fat samples were snap frozen and stored at
−80∘C. RNAwas extracted from adipose tissue using RNeasy
Lipid Tissue Mini Kit (Qiagen, Venlo, The Netherlands),
quantified, and retrotranscribed to cDNA (First Strand cDNA
Synthesis Kit for RT-PCR, Roche, Basel, Switzerland). Quan-
titative polymerase reaction (qRT-PCR)was performed using
the following primers: RBP4 (Hs00198830 m1) and GLUT4
(Hs00168966 m1, Applied Biosystems, Carlsbad, California,
USA). GAPDH was employed as housekeeping gene. Gene
expression was quantified by ΔΔCt methods as previously
described [27, 28].
2.4. Statistical Analysis. From the available data we hypoth-
esized mean serum RBP4 levels in HD twice greater than
in C [22, 23, 29–31] and a standard deviation equal to the
half of the mean; thus we estimated to enrol at least 15
participants per group in order to achieve a power greater
than 90% in stating a difference between the two groups.
We could not find any information on tissue expression of
RBP4 and GLUT4 useful to build up a statistical predic-
tion. The Shapiro-Wilk’s test was used to test the normal
distribution of quantitative variables. If they were normally
distributed, mean and standard deviation (SD) were used
to summarize the results; otherwise, we used median and
interquartile range (IQR; 25∘–75∘ percentile). Parametric
or nonparametric tests were used to compare quantitative
variables (𝑡-test or Man-WhitneyU test for independent data
for comparisons between two groups and Anova or Kruskall
Wallis test for comparisons among more than two groups).
The chi-squared statistics or Fisher’s exact test, as appropriate,
were applied to compare qualitative variables. 𝑃 < 0.05 was
considered statistically significant. Pearson’s 𝑟 coefficient was
used to evaluate the correlation between parameters. All tests
were two-sided. Data analysis was performed with STATA
statistical package (version 9; Stata Corporation, College
Station, 2008, Texas, USA).
3. Results
3.1. Demography. We enrolled 16 regular HD patients (51.5
(44.0–59.7) years, 12 males) with the mean duration of
dialysis being 28 ± 22 months, of whom 7 underwent renal
transplantation after their enrolment. 16 healthy subjects
(51.0 (44.0–58.2) years, 12 males) were the C. As shown in
Table 1 the baseline demographic characteristics of the two
groups were similar: 75% were male with no differences
regarding age and BMI, personal and familiar history of
cardiovascular events, diabetes, lipid disorders, smoking, and
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Table 1: Demographic characteristics.
Hemodialysis Controls 𝑃 value
Number of participants 16 16 —
Male, % 75% 75% NS
Age, years (median, 25∘–75∘ IQR) 51.5 (44.0–59.7) 51.0 (44.0–58.2) NS
BMI, Kg/m2 (mean, ±SD) 24.4 ± 4.0 24.4 ± 3.0 NS
SBP, mmHg (mean, ±SD) 140 ± 26 122 ± 10 0.02
DBP, mmHg (mean, ±SD) 80 ± 13 78 ± 8 NS
Heart rate, bpm (mean, ±SD) 77 ± 11 70 ± 8 NS
History of cardiovascular events, % 14.6% 0 NS
Family history of cardiovascular events, % 60.0% 56.2% NS
Family history of diabetes, % 40.0% 50.0% NS
History of hypertension, % 81.25% 18.7% 0.001
History of lipid disorders, % 25.0% 18.7% NS
Smoking, % 26.6% 12.5% NS
Alcohol abuse, % 0% 6.2% NS
Physical activity, % 13.3% 68.7% 0.003
Patients with normal fasting glucose 16/16 16/16 NS
Patients with normal glycated hemoglobin 14/14 14/15 NS
Total serum protein, g/dL (mean, ±SD) 6.9 ± 0.6 7.2 ± 0.2 NS
Albumin, g/dL (mean, ±SD) 4.3 ± 0.7 4.4 ± 0.1 NS
Hemoglobin, g/dL (mean, ±SD) 11.8 ± 1.5 14.1 ± 1.2 0.001
Serum iron levels, 𝜇g/dL (mean, ±SD) 116.2 ± 47.8 85.6 ± 17.9 0.02
Total serum cholesterol, mg/dL (mean, ±SD) 185 ± 59 205 ± 34 NS
Serum triglyceride, mg/dL (mean, ±SD) 183 ± 97 109 ± 57 0.01
SBP = systolic blood pressure, DBP = diastolic blood pressure, and BMI = body mass index.
alcohol ingestion. There were no differences in total serum
protein levels, serum albumin, and total serum cholesterol,
whereas serum triglyceride levels were significantly higher
in HD group (𝑃 < 0.05). Not surprisingly history of
hypertension, systolic blood pressure, and physical inactivity
were more prevalent in HD compared to C (𝑃 < 0.005, 𝑃 <
0.05, and 𝑃 < 0.005, resp.), furthermore serum hemoglobin
levels were significantly lower while serum iron levels where
higher in HD compared to C (𝑃 < 0.005 and 𝑃 < 0.05),
respectively. Among HD, 94% of the patients had arterial-
venous fistula as vascular access and 53%had residual diuresis
of more than 500ml/24 hours. Of note C reactive protein
(CRP) was normal in all the HD subjects (0.5 ± 0.4mg/dL;
n.v. <0.8mg/dL).
3.2. Insulin Resistance Trait Characterizes ESRD Patient on
Hemodialysis. All HD patients and all the controls (C), but
one, had normal glycosylate hemoglobin (<5.9%, according
to our laboratory limits); all the participants had normal
fasting serum glucose levels (<110mg/dL) (Table 1) with no
differences between the two groups (82.6 ± 12.3mg/dL in
HD versus 83.8 ± 11.8mg/dL in C, NS; Figure 1(a)). On the
contrary, fasting serum insulin levels and HOMA index were
significantly higher in HD compared to C (15.8 ± 12.3 versus
6.7±4.4 𝜇IU/ml, 𝑃 < 0.01; 3.3±2.7 versus 1.4±1.0, 𝑃 < 0.05,
resp.; Figures 1(b) and 1(c)).
3.3. RBP4 Serum Levels Are Elevated in ESRD Patient on
Hemodialysis. Serum RBP4 levels were four times higher in
HD compared to C (176.9 ± 63.2 versus 39.2 ± 17.4mg/L,
𝑃 < 0.005; Figure 1(d)); furthermore, serumRBP4 levels were
lower inHDwith preserved residual diuresis compared to the
anuricHDpatients (141.3±34.2 versus 212.5±67.0mg/L;𝑃 <
0.005; Figure 1(e)). SerumRBP4 levels correlated significantly
and directly with fasting serum glucose levels (𝑃 < 0.05,
𝑟2 = 0.24; Figure 2(a)) but not with insulin levels and HOMA
index (𝑃 = 0.13 and 𝑃 = 0.08, resp.; Figures 2(b) and
2(c)) in HD group. Furthermore, serumRBP4 levels correlate
directly with total serum cholesterol (𝑃 < 0.05, 𝑟2 = 0.45;
Figure 2(d)), serum triglycerides (𝑃 < 0.05, 𝑟2 = 0.60;
Figure 2(e)), and heart rate (𝑃 = 0.05, 𝑟2 = 0.26).
3.4. Adipose Tissue RBP4 and GLUT4 mRNA Expression
Are Decreased in ESRD Patient. Subcutaneous adipose RBP4
mRNA became lower in HD compared to matched sex, age,
and BMI controls (𝑃 < 0.05, Figure 3(a)), while GLUT4
mRNA did not differ between HD and C (0.56 ± 0.40
versus 1.05 ± 0.94 fold change, 𝑃 = 0.25). RBP4 mRNA
correlated positively with subcutaneous GLUT4 expression
(𝑃 < 0.001 and 𝑟2 = 0.75, Figure 3(b)) and negatively with
age (𝑃 < 0.01 and 𝑟2 = 0.47) in the overall population. RBP4
mRNAcorrelated positivelywith kidney function (eGFR,𝑃 <
0.05 𝑟2 = 0.72) in controls. Moreover GLUT4 expression
showed negative correlations with age and BMI (𝑃 < 0.05
and 𝑟2 = 0.31, 𝑃 < 0.01 and 𝑟2 = 0.47, resp.) in the overall
population.
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Figure 1: Fasting serum glucose levels (a), fasting serum insulin levels (b), HOMA index (c), and serum RBP4 (d) in hemodialysis patients
(HD) and controls. Influence of residual diuresis on serum RBP4 in HD patients (e). ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.005.
3.5. RBP4 Serum Levels Are Reduced after Kidney Transplant.
In the 7 patients undergoing renal transplantation serum
RBP4 levels were significantly reduced compared to pretrans-
plant levels (39.6 ± 16.3 versus 132.2 ± 45.2mg/L, resp.,
𝑃 < 0.01; Figure 4(a)); these levels positively correlated with
serum creatinine and fasting serum insulin (𝑃 < 0.01 and
𝑟2 = 0.67; 𝑃 < 0.01 and 𝑟2 = 0.58, resp.; Figures 4(b) and
4(c)). All the patients showed normal fasting serum glucose
(90±11mg/dL) after kidney transplant and serum creatinine
was 1.5 ± 0.64mg/dL. Despite the significant increase of the
BMI (23,6 ± 4.8 versus 25.1 ± 5 kg/m2, 𝑃 < 0.05; Figure 4(d))
accompanied by the increase of fasting serum glucose serum
levels (80.3 ± 11.5 versus 91.1 ± 12.4mg/dL; Figure 4(e)),
serum fasting insulin, HOMA index, total serum cholesterol,
and serum triglyceride did not change significantly (12.6±8.2
versus 8.9±6.0 𝜇IU/ml, 2.5±1.8 versus 2.0±1.5, 187.9±55.7
versus 182.4 ± 52.9mg/dL, and 171.1 ± 46.4 versus 99.4 ±
27.2mg/dL, resp.; NS).
3.6. HDF Lowers RBP4 Circulating Levels in ESRD Patients.
In the patients enrolled in the cross-over study RBP4 cir-
culating levels were significantly reduced by HDF treatment
compared to BD (99.2 ± 48.9 versus 140.1 ± 54.1mg/L, 𝑃 <
0.05; Figure 5(a)). Furthermore, HDF treatment granted 20-
fold greater intradialysis RBP4 removal compared to BD
(Figure 5(b)).
4. Discussion
Our study shows that serumRBP4 levels are four times higher
in ESRD patients on maintenance hemodialysis compared
to subjects with normal renal function. The kidney is the
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Figure 2: Correlation between serum RBP4 levels and fasting serum glucose (a), fasting serum insulin (b), HOMA index (c), total serum
cholesterol (d), and serum triglycerides (e) in hemodialysis patients (HD).
main site of RBP4 clearance because RBP4 is filtered by
the glomeruli and it is further metabolized by tubular cells.
Therefore, it can be hypothesized that defective RBP4 renal
clearance is the main cause of RBP4 accumulation in ESRD
patients and that RBP4 retention is not obviated by standard
bicarbonate dialysis because its molecular weight is in the
range of middle molecules [13]. As expected from studies
on renal handling of middle molecules, residual diuresis
preserved some RBP4 excretion and was associated with
lower serum levels of RBP4 [32]. Furthermore, an ultimate
evidence of the strict dependence of RBP4 serum levels
on renal function is provided by our findings that serum
RBP4 levels decreased proportionally with renal function
recovery in kidney graft recipients. Finally RBP4 genewas less
expressed in adipocytes of HD compared to paired C, a result
that strengthens the evidence that increased production of
RBP4 in adipose tissue did not account for its high blood
levels in HD. In our study we carefully excluded patients
with any general risk factor for metabolic and cardiovascular
disorders, but those associated with renal failure and dialysis.
In particular to prevent sampling biases we matched patients
and controls for sex, age, and BMI and we have enrolled
only patients that were in the range advised by guidelines
as for Hb levels, indexes of bone metabolism, and dialysis
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Figure 5: Effect of HDF treatment on RBP4 circulating levels (cross-over study, a). RBP4 intradialysis removal (b). ∗𝑃 < 0.05.
performance [25]. Normal blood glucose levels required a
threefold increase of serum insulin levels in HD subjects
compared to controls, a state of IR that was confirmed by the
HOMA index. For the first time we show that serum levels of
RBP4 correlated directly with fasting glucose in ESRD under-
going dialytic treatment. In the absence of alternative causes
of IR, RBP4 remains the only identifiable culprit for IR in our
patients and the retention of RBP4 assumes the role of main
pathogenic mechanism for metabolic dysfunction in ESRD.
Interestingly, RBP4 levels were significantly correlated also
with serum cholesterol and serum triglyceride thus confirm-
ing its link with IR and metabolic syndrome [15, 17]. Finally
we found a positive correlation between RBP4 and heart rate
an indirect marker of adrenergic drive hyperactivation that
invariably characterizes the different aspects of the metabolic
syndrome [33]. It has been shown that RBP4 serum levels are
associated with kidney function rather than type II diabetes
in nondialytic population with moderate kidney disease [30].
However, our study provides some insights regarding RBP4
role on IR in a different setting characterized by severe kidney
disease requiring hemodialysis. In this regard our data are
confirmatory of previous findings in experimental studies
in murine models of type II diabetes and uremia [15, 34].
High RBP4 serum levels and low adipose RBP4 mRNA in
ESRD patients undergoing dialysis figure a feedback system
where GLUT4 mRNA expression is also involved: excess
RBP4 might operate a self-limitation by inhibiting RBP4
synthesis in one hand, while it inhibits GLUT4 expression
contributing to insulin resistance in the other [35, 36]. These
findings depict a scenario in which RBP4 and GLUT4 are
reciprocally connected in a system that participates in glucose
metabolism and whose disruption leads to RBP4-driven IR
in the ESRD milieu [37]. The mechanisms that mediate the
cross-talk between circulating RBP4 and its tissue expression,
as well as the molecular transducers of RBP4, require full
exploration in ESRD population. Our data show that poor
RBP4 clearance can be attained with standard bicarbonate
dialysis using dialyzers with low molecular cut-off; on the
contrary we demonstrated that the dialyzer with higher cut-
off employed in HDF can actually efficiently clear RBP4
(Figure 6).This observation is a sound base for future studies
aimed to prove that RBP4 removal by HDF can modulate IR
in ESRD patients.
RBP4
excretion
ESRD Circulating RBP4
Adipose tissue RBP4 expression
Adipose tissue GLUT4 expression
?
?
Glucose uptake
Insulin resistance
HDF
Figure 6: Hypothesis about pivotal role of the kidney in RBP4
mediated insulin resistance (IR) in End Stage Renal Disease (ESRD):
possible intervention by HDF.
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